Inactive Instrument

Analyst Reco. Mirati Therapeutics

Equities

MRTX

US60468T1051

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Citigroup Downgrades Mirati Therapeutics to Neutral From Buy, Raises Price Target to $59 From $48	12-20	MT
Stifel Downgrades Mirati Therapeutics to Hold From Buy, Cuts Price Target to $59 From $83	11-07	MT
Scotiabank Upgrades Mirati Therapeutics to Sector Perform From Sector Underperform, Raises Price Target to $58 From $24	10/10/23	MT
TD Cowen Downgrades Mirati Therapeutics to Market Perform From Outperform	10/10/23	MT
Piper Sandler Downgrades Mirati Therapeutics to Neutral From Overweight, Raises Price Target to $58 From $45	10/10/23	MT
B. Riley Downgrades Mirati Therapeutics to Neutral From Buy After Announced Sale to Bristol Myers Squibb, Lowers PT to $60 From $65	09/10/23	MT
Scotiabank Upgrades Mirati Therapeutics to Sector Perform From Sector Underperform, Raises Price Target to $58 From $24	09/10/23	MT
JMP Securities Downgrades Mirati Therapeutics to Market Perform From Market Outperform	09/10/23	MT
Jefferies Downgrades Mirati Therapeutics to Hold From Buy, Adjusts Price Target to $58 From $55	09/10/23	MT
Here we go again	06/10/23
BMO Capital Raises Price Target on Mirati Therapeutics to $72 From $31, Keeps Market Perform Rating	06/10/23	MT
JMP Securities Adjusts Price Target on Mirati Therapeutics to $82 From $58, Keeps Market Outperform Rating	06/10/23	MT
B. Riley Raises Mirati Therapeutics' Price Target to $65 From $45, Says Adcomm Outcome a Positive; Keeps Buy Rating	06/10/23	MT
Citigroup Upgrades Mirati Therapeutics to Buy From Neutral, Adjusts Price Target to $48 From $51	10/08/23	MT
Oppenheimer Adjusts Mirati Therapeutics Price Target to $62 From $56, Maintains Outperform Rating	09/08/23	MT
BMO Capital Adjusts Price Target on Mirati Therapeutics to $31 From $40, Maintains Market Perform Rating	09/08/23	MT
Piper Sandler Assumes Mirati Therapeutics at Overweight With $45 Price Target	09/08/23	MT
Morgan Stanley Adjusts Price Target on Mirati Therapeutics to $37 From $42, Keeps Equalweight Rating	09/08/23	MT
B. Riley Upgrades Mirati Therapeutics to Buy From Neutral based on Clinical Updates for G12C, PRMT5 Programs; Keeps $45 Price Target	09/08/23	MT
CORRECTION : Scotiabank Starts Mirati Therapeutics at Sector Underperform With $20 Price Target	27/07/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mirati Therapeutics

Equities

MRTX

US60468T1051

Analyst Reco.

Filters